Literature DB >> 34395318

The Relationship between Tumor-infiltrating Lymphocytes (TILs) and Nasopharyngeal Carcinoma (NPC): A Systematic Review.

Awal Prasetyo1,2, Jethro Budiman3, Udadi Sadhana1,2.   

Abstract

INTRODUCTION: Nasopharyngeal carcinoma (NPC) is a rare and aggressive head and neck squamous cell carcinoma worldwide. Tumor-infiltrating lymphocytes (TILs) have been studied and reported to be effective targets of drugs on cancer and were related to the prognostic value. The aim of the study was to look systematically into the current literature and carefully analyze the results to explore the relationship of TILs and NPC.
MATERIALS AND METHODS: Three independent reviewers conducted the literature search, searching for articles published in January 2000-January 2020 and fulfilling inclusion and exclusion criteria. The lead author independently assessed the risk of bias of each of the included studies and discussed their assessments with the other two authors to achieve consensus. Of the 1233 articles identified in database searching, 12 articles met the criteria for this review.
RESULTS: The majority of the study designs were cohort (9 of 12 studies). Most of the studies discussed the prognostic significance of TILs in NPC (nine studies), two studies reported the expanded TILs for the treatment of NPC, and one study reported TILs based on one gene expression.
CONCLUSION: TILs in NPC are related to the prognostic factor and development of the immunotherapy. High TILs were associated with better outcome and survival rate; and TILs have been claimed to reflect an effective anti-tumor immune response, immune response inducer, delayed tumor progression, and improving the cancer-immune microenvironment. The understanding of TILs in NPC based on gene expression becomes important information to learn more about the relationship of TILs and NPC.

Entities:  

Keywords:  Immunology; Nasopharyngeal Carcinoma; Tumor-Infiltrating Lymphocytes

Year:  2021        PMID: 34395318      PMCID: PMC8339891          DOI: 10.22038/ijorl.2021.51405.2733

Source DB:  PubMed          Journal:  Iran J Otorhinolaryngol        ISSN: 2251-7251


Introduction

Nasopharyngeal carcinoma (NPC) is a rare and aggressive head and neck squamous cell carcinoma worldwide; but it is endemic in a few areas, like Southern China, Southeast Asia, North Africa, and the Arctic (1-4). The incidence in Southern China and Southeast Asia is high with the majority of tumors being undifferentiated and non-keratinizing carcinomas. On the contrary, NPCs of non-endemic areas (such as Northern Europe) can be keratinizing or non-keratinizing (5). Based on the Global Cancer Observatory (GLOBOCAN), 129.079 new cases of NPC were diagnosed in 2018 and were associated with 72.987 deaths (5,6). One of the most striking and consistent characteristics of NPC is the presence of a very abundant lymphocyte infiltrate with a high rate of local invasion and locoregional lymphatic metastasis (5,7). The tumor has a multifactorial etiology and differs from other head and neck cancers by characteristic histological findings (3,8). The prognosis of NPC was improved significantly with the development of the treatment (radiotherapy, chemotherapy, and surgical) (1,3). For recent years, the prognosis and the strategy treatment of NPC used the tumor–node–metastasis (TNM) cancer staging system, but it remained large variations in the patient's prognosis who were also undergoing the similar treatment with the same stage so the TNM system was maybe not enough to evaluate the entire NPC status or guide treatments (1,9). The malignant phenotypes of cancers are also defined by the immune cells activated in the tumor microenvironment (TME) (2,10). TME consists of immune cells (including tumor-infiltrating lymphocytes/TILs), endothelial cells, mesenchymal cells, inflammatory mediators and extracellular matrix molecules (1,2,11). In TME, tumor-infiltrating lymphocytes (TILs) are one major type of nontumor components and have been validated for diagnostic and prognostic assessment of tumors (1,2,11). TILs are immune cells that are triggered by the host's immune response to the tumor; including T cells (CD4+ T helper lymphocytes/ Th, CD8+ cytotoxic T lymphocytes/ CTLs, and FOXP3+ regulatory T-cells/ Tregs), macrophages, dendritic cells, and mast cells (1,12,13). TILs have been studied and reported to be effective targets of drugs on cancer and were related to the prognostic value. Mechanism studies confirmed that TILs have a dual role by conducting both host immune defense and tumor progression (1,5). The relationship of TILs and NPC have been reported and explained in various studies, but there was no systematic review about the relationship of them. The aim of the study was to look systematically into the current literature and carefully analyze the results to explore the relationship of TILs and NPC.

Materials and Methods

Scope of the review: inclusion and exclusion criteria Inclusion criteria: 1. Publication type: full-text articles discussing the relationship of TILs and NPC primary studies of every design (case study, case series, cross-sectional, case control, cohort, and clinical trial) 2. Languange of publication: english 3. Time of publication: January 2000-January 2020 4. Methodology: studies included must explain the relationship of TILs and NPC Exclusion criteria: 1. Objective and outcome measures are not relevant (are not about the relationship of TILs and NPC) 2. Confounding variables are related to outcome in the relationship of TILs and NPC Literature search This systematic review was conducted in accordance with Cochrane handbook for systematic reviews and is reported by using the guideline of preferred reporting items for systematic review and meta-analysis (PRISMA) (14,15). A systematic search strategy was followed in these electronic databases: Cambridge Core, Clinical Key, Ebsco, Emerald Insight, JSTOR, Medline, Nature, Proquest, Pubmed, Science Direct, Scopus, and Springer Link. The search was conducted using the following keywords for title and abstract: (tumor infiltrating lymphocyte) AND (nasopharyngeal cancer OR nasopharyngeal carcinoma OR nasopharyngeal tumor). The reference lists of retrieved papers were also examined to avoid missing any published data (including grey literature in the library and hand searching). Data collection and analysis Studies were selected for retrieval after two independent reviewers (AP and JB) had collected titles and abstracts identified in electronic searches. The results of the two reviewers were compared by a third independent reviewer (US), and any differences of opinion were resolved by discussion. Full papers from potential studies were independently assessed by the investigators (AP and JB). All studies selected for this systematic review were screened by two reviewers independently to validate the results (AP and JB). The data from all retrieved studies were presented in a summary table featuring key points of each study (Table.5). The following data were collected: first author, country, and year; study design, sample size and characteristic, outcome measure, and result.
Table 5

Study characteristic

No. First author, country, year Study design Sample size (n) and characteristic:age (year), gender (male, female), NPC characteristic Outcome measure Result
1.Almangush A, Finland, 2018[5]Cohort115CharacteristicAge: 58 (12-85)Gender: 80,35NPC Characteristic:Type I: 28Type II: 19Type III: 68Stage I: 15Stage II: 29Stage III: 40Stage IV: 31The prognostic significance of TILs in NPC

NPC with low intra-tumoral TILs had poor OS (HR: 2.55, 95%CI: 1.60-4.50,

P<0.001) and poor DSS (HR: 2.02, 95%CI: 1.16-3.52, p: 0.015).

Keratinized tumors with low intra-tumoral TILs were associated with a poor OS (HR: 3.94, 95%CI: 2.17-7.15, P< 0.001) and a poor DSS (HR:2.97, 95%CI: 1.46-6.05, p: 0.009).

2.Chan OSH, Hongkong, 2017[22]Cohort161CharacteristicAge: 53 (27-88)Gender: 117,44NPC Characteristic:Stage I: 2Stage II: 13Stage III: 78Stage IV: 68Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer (the prognostic significance of TILS in NPC)

75% of tumors expressed PD-L1 on TILs and 24% on TC.

High CD8+ TILs were associated with better OS (HR: 0.53, 95%CI: 0.34-0.84,

P: 0.0059). and PFS (HR: 0.57, 95%CI: 0.38-0.85, p: 0.006).

3.He J, China, 2012[27]Experimental15Characteristic: not describedEx vivo expansion of TILs from NPC for adoptive immunotherapy

Young TIL cultures comprised of more than 90% of CD3+ T cells, a variable percentage of CD3+CD8+ and CD3+ CD4+ T cells, and less than 10% of CD3-CD16+ NK cells, a similar phenotype of EBV-CTL cultures from PBMCs.

TIL cultures secreted high levels of the Th1 cytokines, IFNγ and TNF-α, and low levels of the Th2 cytokines, IL-4 and IL-10.

Young TILs could recognize autologous EBV-transformed B lymphoblast cell lines, but not autologous EBV-negative blast cells or allogeneic EBV-negative tumor cells.

4.Larbcharoensub N, Thailand, 2018[21]Cohort114Age: 51.6±12.7Gender: 77, 37NPC Characteristic:Stage I: 3Stage II: 14Stage III: 41Stage IV: 48Characterization of PD-L1 and PD-1 expression and CD8+ TILs in Epstein-Barr Virus-associated NPC (the prognostic significance of TILS in NPC)

PD-L1 was expressed in ≥ 1% of TCs in 69% of patients, in ≥ 50% of TCs in 12% of patients, and ≥ 5% of either TCs or infiltrating immune cells in 71% of patients.

CD8+ TILs were present in tumors from all patients.

High CD8+ TILs levels in NPC were associated with a longer OS.

5.Li J, China, 2015[26]Experimental23CharacteristicAge: 45.5 (29-62)Gender: 18, 5NPC Characteristic: Type III at an advanced stage (stage III-IV) without distant organ metastasis at diagnosisThe safety and antitumor activity of ACT using expanded TILs following CCRT in patients with locoregionally advanced NPC

Three patients failed to produce sufficient TILs (drop out).

Only mild AEs including grade 3 neutropenia (1/23, 5%) consistent with immune-related causes, were observed.

19 of 20 patients exhibited an objective antitumor response, and 18 patients displayed DFS longer than 12 mo after ACT.

6.Lu J, China, 2018[7]Cohort197CharacteristicAge: not describedGender: 146,51NPC Characteristic:Stage I: 10Stage II: 30Stage III: 62Stage IV: 95Analysis of inflammatory cell infiltration and the prognosticimpact on NPC

The patients with NPC with a low density of FOXP3+, CD8+ TILs, neutrophils, and mast cells showed a significantly longer OS and PFS (p: 0.006, p: 0.018, p: 0.002).

The prognostic impacts of CD8+ TILs (HR: 1.700, p: 0.036) and FOXP3+ (HR:1.714, p: 0.034) on OS were not proved.

7.Luo M, China, 2019[1]Cross sectionalNPC: 12Normal: 4Characteristic: not describedTILs in NPC based on gene expression

NPC samples contained a higher proportion for M1 macrophages, whereas memory B cells and CD4 memory resting T cells were relatively lower.

High M1 macrophages, memory B cells, and CD4 memory resting T cells were associated with a better survival rate (p: 0.286, p: 0.509, p: 0.048).

8.Oudejans J J, Indonesia, 2002[25]Cohort43CharacteristicAge: 48Gender: 32, 11NPC Characteristic: without evidence of distant metastasesThe prognostic significance of GrB/ CD8+ TILs in NPC

The presence of a high percentage (>25%) of GrB + TILs appeared to be a very strong predictor of a rapid fatal clinical outcome, independent of stage.

9.Ono T, Japan, 2018[2]Cohort66CharacteristicAge: 59.5 (13-85)Gender: 54,12NPC Characteristic:Type I: 18Type II-III: 48Stage I: 3Stage II: 18Stage III: 25Stage IV: 20The prognostic significance of TILs in NPC

CD8+ TILs were significant predictive factor for PFS (HR: 0.36, 95%CI: 0.15-0.88, p: 0.025) and OS (HR: 0.30, 95%CI: 0.12-0.73, p: 0.008).

10.Ooft ML, Netherland, 2017[23]Cohort92CharacteristicAge: 53.45Gender: 63,26NPC Characteristic:Type I: 12Type II-III: 76The prognostic significance of TILs in NPC

EBV positive NPC contains significantly more CD3+, CD4+, and CD8+ TILs than EBV negative NPC.

In the whole NPC group, increased CD8+ count is associated with better OS (HR: 0.219. 95%CI: 0.075-0.640), but also in cases with PDL1 co-expression (HR: 0.073, 95%CI: 0.010-0.556).

In EBV positive NPC co-expression of CD8+ and PDL-1 showed better DFS (HR:0.407, 95%CI: 0.195-0.850) and OS (HR 0.170, 95%CI: 0.037–0.787).

11.Wang Y, China, 2018[9]CohortTraining set: 591Gender: 363, 228NPC Characteristic:Stage I-II: 127Stage III-IV: 464Validation set: 584Gender: 330, 254NPC Characteristic:Stage I-II: 130Stage III-IV: 454Independent set: 304Gender: 218, 86NPC Characteristic:Stage I-II: 44Stage III-IV: 260The prognostic significance of TILs in NPC

High TILs in the training set were significantly associated with favorable DFS (HR: 0.41, 95%CI: 0.28-0.58, p< 0.001), OS (HR 0.42, 95%CI: 0.27-0.64, p < 0.001), DMFS, (HR: 0.37, 95%CI: 0.23-0.58, p< 0.001 and LRRFS (HR: 0.43, 95%CI :0.25-0.73, p: 0.002).

12.Zhang Y, China, 2010[24]Cohort106CharacteristicAge: 49 (22-73)Gender: 84,22NPC Characteristic:Type I: 1Type II: 13Type III: 92Stage I-II: 38Stage III-IV: 68The prognostic significance of TILs in NPC

The density of FOXP3+ TILs or Foxp3+ TILs combined with GrB+ TILs together were associated with better OS and PFS (p< 0.01).

Low density of CD8+TILs or high ratio of FOXP3+TILs to CD8+TILs was correlated with better PFS in early-stage patients (Stages I and II, p< 0.05).

Abbreviation: ACT: adoptive cell therapy AEs: adverse events          CCRT: concurrent chemoradiotherapy           CD: cluster of differentiation            CI: confidence interval            DFS: disease-free survival           DMFS: distant metastasis-free survival           DSS: disease specific survival            EBV: epstein-barr virus            FOXP3: forkhead box p3 GrB: Granzyme B           HR: hazard ratio           IFN-γ: interferon-gamma            IL: interleukin            LRRFS: local-regional recurrent free survival          

mo: month NK: natural killer            NP: non-malignant nasopharyngeal            OS: overall survival            p: probability            PBMC: peripheral blood mononuclear cells            PFS: progression-free survival            Treg: regulatory T cells            TCs: tumor cells

Quality assessment The lead author independently assessed the risk of bias of each of the included studies and discussed their assessments with the other two authors to achieve consensus. Newcastle-ottawa scale adapted for cross-sectional studies, newcastle–ottawa scale cohort version, cochrane risk of bias were used to assess the methodological quality of the studies (14,16–18). Newcastle-ottawa scale adapted for cross-sectional studies was used to assess cross-sectional studies, interpretation of total score was: 9 to 10 points were considered in very good studies, 7 to 8 points were considered in good studies, 5 to 6 points were considered in satisfactory studies, and 0 to 4 points were considered in unsatisfactory studies (16). Newcastle–ottawa scale cohort version was used to assess cohort study, interpretation of total score was: ≥7 points were considered in good studies, 5-6 points were considered in fair studies, <5 points were considered in poor studies (17–20). Cochrane risk of bias was used to asses randomized control trial study (experimental), whose results were either high risk or some concerns or low risk (14).

Results

Selection of articles for review Figure 1 summarized the identified, screened, and included articles for review. Initially, 1233 peer-reviewed articles were identified from electronic databases and an additional 18 articles were identified through other sources (including search engine, gray paper, and hand searching).
Fig 1

Preferred reporting items for systematic reviews and meta-analysis (PRISMA)

After removing duplicates, 251 articles remained for the title and abstract screening. Articles that did not meet the inclusion and exclusion criteria were not further screened. Twenty-two articles were screened for eligibility of which 12 articles met all the inclusion criteria. Assessment of study validity (risk of bias) All eligible studies were associated with the relationship of TILs and NPC. Table 1 provides quality scores for cross-sectional study and got 5 points that were considered in the satisfactory study. Table 2 provides quality scores for cohort studies, all studies get 5-7 points that were considered in fair and good studies.
Table 1

Newcastle-Ottawa scale adapted for cross-sectional study

No.First author, yearSelectionComparabilityOutcomeTotal
123412
1.Luo M, 2019 (1)*****5
Table 2

Newcastle-Ottawa scale (cohort study)

No.First author, yearSelectionComparabilityOutcomeTotal
1234123
1.Almangush A, 2018[5]*****5
2.Larbcharoensub N, 2018[21]** ***5
3.Lu J, 2018[7]*****5
4.Ono T, 2018[2]*****5
5.Wang Y, 2018[9]*******7
6.Chan OSH, 2017[22]*****5
7.Ooft ML, 2017[23]*****5
8.Zhang Y, 2010[24]*****5
9.Oudejans J J, 2002[25]*****5

*Maximum point for comparability were 2

Table 3 and table 4 provide quality scores for randomized control trial study, all studies were considered in some concerns and low risk.
Table 3

Cochrane risk of bias 1: Li J, 2015[26]

No. Domain Description of domain Results
1. Domain 1 risk of bias arising from the randomization process some concerns
2.Domain 2risk of bias due to deviations from the intended interventions (effect of adhering to intervention)low risk
3.Domain 3missing outcome datalow risk
4.Domain 4risk of bias in measurement of the outcomelow risk
5.Domain 5risk of bias in selection of the reported resultlow risk
Table 4

Cochrane risk of bias 2: He J, 201227

No. Domain Description of domain Results
1.Domain 1 risk of bias arising from the randomization process some concerns
2.Domain 2risk of bias due to deviations from the intended interventions (effect of adhering to intervention)low risk
3.Domain 3missing outcome datalow risk
4.Domain 4risk of bias in measurement of the outcomelow risk
5.Domain 5risk of bias in selection of the reported resultlow risk
Newcastle-Ottawa scale adapted for cross-sectional study Preferred reporting items for systematic reviews and meta-analysis (PRISMA) Newcastle-Ottawa scale (cohort study) *Maximum point for comparability were 2 Cochrane risk of bias 1: Li J, 2015[26] Cochrane risk of bias 2: He J, 201227 Study characteristic Study characteristics for the included studies could be seen in table 5. The majority of the study designs were cohort (9 of 12). Most of the studies discussed the prognostic significance of TILs in NPC (nine studies), two studies reported the expanded TILs for the treatment of NPC, one study reported TILs based on one gene expression. Study characteristic NPC with low intra-tumoral TILs had poor OS (HR: 2.55, 95%CI: 1.60-4.50, P<0.001) and poor DSS (HR: 2.02, 95%CI: 1.16-3.52, p: 0.015). Keratinized tumors with low intra-tumoral TILs were associated with a poor OS (HR: 3.94, 95%CI: 2.17-7.15, P< 0.001) and a poor DSS (HR:2.97, 95%CI: 1.46-6.05, p: 0.009). 75% of tumors expressed PD-L1 on TILs and 24% on TC. High CD8+ TILs were associated with better OS (HR: 0.53, 95%CI: 0.34-0.84, P: 0.0059). and PFS (HR: 0.57, 95%CI: 0.38-0.85, p: 0.006). Young TIL cultures comprised of more than 90% of CD3+ T cells, a variable percentage of CD3+CD8+ and CD3+ CD4+ T cells, and less than 10% of CD3-CD16+ NK cells, a similar phenotype of EBV-CTL cultures from PBMCs. TIL cultures secreted high levels of the Th1 cytokines, IFNγ and TNF-α, and low levels of the Th2 cytokines, IL-4 and IL-10. Young TILs could recognize autologous EBV-transformed B lymphoblast cell lines, but not autologous EBV-negative blast cells or allogeneic EBV-negative tumor cells. PD-L1 was expressed in ≥ 1% of TCs in 69% of patients, in ≥ 50% of TCs in 12% of patients, and ≥ 5% of either TCs or infiltrating immune cells in 71% of patients. CD8+ TILs were present in tumors from all patients. High CD8+ TILs levels in NPC were associated with a longer OS. Three patients failed to produce sufficient TILs (drop out). Only mild AEs including grade 3 neutropenia (1/23, 5%) consistent with immune-related causes, were observed. 19 of 20 patients exhibited an objective antitumor response, and 18 patients displayed DFS longer than 12 mo after ACT. The patients with NPC with a low density of FOXP3+, CD8+ TILs, neutrophils, and mast cells showed a significantly longer OS and PFS (p: 0.006, p: 0.018, p: 0.002). The prognostic impacts of CD8+ TILs (HR: 1.700, p: 0.036) and FOXP3+ (HR:1.714, p: 0.034) on OS were not proved. NPC samples contained a higher proportion for M1 macrophages, whereas memory B cells and CD4 memory resting T cells were relatively lower. High M1 macrophages, memory B cells, and CD4 memory resting T cells were associated with a better survival rate (p: 0.286, p: 0.509, p: 0.048). The presence of a high percentage (>25%) of GrB + TILs appeared to be a very strong predictor of a rapid fatal clinical outcome, independent of stage. CD8+ TILs were significant predictive factor for PFS (HR: 0.36, 95%CI: 0.15-0.88, p: 0.025) and OS (HR: 0.30, 95%CI: 0.12-0.73, p: 0.008). EBV positive NPC contains significantly more CD3+, CD4+, and CD8+ TILs than EBV negative NPC. In the whole NPC group, increased CD8+ count is associated with better OS (HR: 0.219. 95%CI: 0.075-0.640), but also in cases with PDL1 co-expression (HR: 0.073, 95%CI: 0.010-0.556). In EBV positive NPC co-expression of CD8+ and PDL-1 showed better DFS (HR:0.407, 95%CI: 0.195-0.850) and OS (HR 0.170, 95%CI: 0.037–0.787). High TILs in the training set were significantly associated with favorable DFS (HR: 0.41, 95%CI: 0.28-0.58, p< 0.001), OS (HR 0.42, 95%CI: 0.27-0.64, p < 0.001), DMFS, (HR: 0.37, 95%CI: 0.23-0.58, p< 0.001 and LRRFS (HR: 0.43, 95%CI :0.25-0.73, p: 0.002). The density of FOXP3+ TILs or Foxp3+ TILs combined with GrB+ TILs together were associated with better OS and PFS (p< 0.01). Low density of CD8+TILs or high ratio of FOXP3+TILs to CD8+TILs was correlated with better PFS in early-stage patients (Stages I and II, p< 0.05). Abbreviation: ACT: adoptive cell therapy AEs: adverse events          CCRT: concurrent chemoradiotherapy           CD: cluster of differentiation            CI: confidence interval            DFS: disease-free survival           DMFS: distant metastasis-free survival           DSS: disease specific survival            EBV: epstein-barr virus            FOXP3: forkhead box p3 GrB: Granzyme B           HR: hazard ratio           IFN-γ: interferon-gamma            IL: interleukin            LRRFS: local-regional recurrent free survival mo: month NK: natural killer            NP: non-malignant nasopharyngeal            OS: overall survival            p: probability            PBMC: peripheral blood mononuclear cells            PFS: progression-free survival            Treg: regulatory T cells            TCs: tumor cells

Discussion

The relationship of TILs and NPC The prognostic significance of TILs in NPC was explained in nine studies. Six studies showed that high TILs were associated with better outcomes and survival rates. Wang Y, et al. (2018) reported that stromal TILs were found to be a superior parameter with a high reproducibility than intratumoral TILs. The limited number and restricted range of intratumoral TILs might be an explanation for the inferior prognostic value of intratumoral TILs; intratumoral TILs are more heterogeneous and are relatively difficult to observe on hematoxylin-eosin stained slides. As the combination of intratumoral and stromal TILs, TILs seem to be the strongest survival predictor of NPC outcomes (9). Generally, the predominance of TILs has been claimed to reflect an effective anti-tumor immune response, immune response inducer, delayed tumor progression, and improving the cancer-immune microenvironment (2,5,9,23,26). TILs also can recognize tumor antigens and instigate tumor rejection (23) Treg cells in TILs can suppress naïve T cells and effector T cells and are defined as immune suppression cells that inhibit antitumor immunity and help tumor cell immune evasion. The mechanisms of suppressing proliferation of naïve or effector T cells of these Treg cells are controlled by cell-to-cell contact or secreting cytokines interleukin-10 (IL-10) and tumor growth factor-beta (TGF-β). However, it has been identified that some tumor-derived Treg cells with the tumor antigen specificity could recognize the autologous antigen-specific tumor cell and secret interferon-gamma (IFN-γ) in vitro (5,24).On the contrary, we found three studies that explain the correlation of high TILs and poor prognosis in NPC. An explanation might be the functional inactivation of CD8+ CTL (cluster of differentiation 8-cytotoxic T lymphocyte) in NPC (7). Li J, et al. (2007) has demonstrated that CD8+ CTLs could increase PD-1 (program death-1) expression and reduce CD3 expression, resulting in an impaired tumor-specific immunity (4). In addition, CD8+ CTL may upregulate the expression of PD-L1 (program death ligand-1) and indoleamine-2,3-dioxygenase in tumor cells, recruit Tregs in the tumor microenvironment, and then promote tumor immune escape by the production of CCL22 (C-C motif chemokine ligand 22) and IFN-γ (7). Lu J, et al. (2018) reported that CTL has been assigned an important role in antitumor immunity; but in the research, CD8+ CTL density was positively associated with poor PFS in early-stage patients. Therefore, a possible explanation for this result is that a CD8+ CTL function is impaired thus the CD8+ CTL could not kill the tumor cell in NPC TILs (7). Another possibility is that the acute immune response could induce the spreading of tumor cells to the regional lymphoid node (24). These three studies seem to contradict the most finding, but the discrepancy may be due to small sample sizes, racial origins, and limited statistical power (9,24). Two studies explained the use of TILs in immunotherapy (26,27). Adoptive cell therapy (ACT) using TILs have an antitumor effect and can induce an immune response in NPC. This study demonstrated that NPC patients can tolerate adoptive cell therapy with TILs following CCRT (concurrent chemoradio- therapy) and experience sustained antitumor activity and anti-EBV (epstein-barr virus) immune responses. Additionally, a larger phase II trial is in progress. Although TILs have shown some therapeutic effects, their prognostic effect has been overlooked. The study conducted by Li J, et al. (2015) emphasized that TILs are a powerful, independent predictor of DFS (disease-free survival) in NPC patients and deserve further investigation (9,26). Another study explained about ex vivo expansion of TILs from NPC patients for adoptive immunotherapy. Ex vivo expansion of TILs from NPC patients may have several potential advantages. First, the experimental method for establishing young TILs is simple and rapid, and TIL cultures can be successfully established for most NPC patients with tumor biopsy tissues. Second, the young TILs cultures have a low non-specific activity to human leukocyte antigen (HLA) mismatched cells because these cultures contain a high percentage of CD3+ T cells and a low percentage of CD3-CD16+ NK cells so can minimize the rejection reaction. Finally, young TIL cultures have a stable EBV specific activity and contain a higher percentage of tumor recognized EBV antigen-specific T cells compared to EBV-CTLs stimulated by auto LCLs (lymphoblast cell lines) from peripheral blood (26,27). One study explained about TILs in NPC based on gene expression by using CIBERSORT (a gene expression-based deconvolution algorithm)(1). The fraction of 22 immune cells in NPC was associated with tumorigenesis (gain of malignant properties in normal cells, which have been generalized as the hallmarks of cancer), which is potentially useful for the development of immunotherapy (1,28). This research found that NPC samples contained a higher proportion for M1 macrophages, whereas memory B cells and CD4 memory resting T cells were relatively lower; and all of this may be associated with tumorigenesis of NPC. These differences of immune cells might be important determinants for the prognosis. The survival analyses based on the cancer genome atlas (TCGA) database showed that CD4 memory resting T cells would be a predictive outcome signature in NPC. Therefore, M1 macrophages, memory B cells, and CD4 memory resting T cells may play pivotal roles in the development of NPC and the differentiation may be possible therapeutic targets (1,5,12,13). Strength and limitation of the study The present systematic review involved studies that reported 12 studies related to the relationship of TILs and NPC (nine studies about the prognostic significance of TILs in NPC, two studies about the development treatment of TILs in NPC, and one study about gene expression of TILs in NPC). In addition, a comprehensive literature search was followed, as well as bias protection methods such as three independent reviewers. The limitation of the study was related to the minimal sample and one area of each study, most of the studies were observational studies (there were only two randomized controlled trial study/RCT), and there was language bias (only english language was included in this study). Future implication The current systematic review is expected to be a scientific consideration to clinician-related the application of TILs in NPC, like as prognostic factor or the development of the treatment of NPC, and general information related to the relationship of TILs and NPC for the public society. Further research is needed on the other relationship of TILs and NPC.

Conclusion

Tumor-infiltrating lymphocytes (TILs) in nasopharyngeal carcinoma (NPC) are related to the prognostic factor and development of the immunotherapy. High TILs were associated with better outcome and survival rate; and TILs have been claimed to reflect an effective anti-tumor immune response, immune response inducer, delayed tumor progression, and improving the cancer-immune micro- environment. The understanding of TILs in NPC based on gene expression becomes important information to learn more about the relationship of TILs and NPC.
  23 in total

1.  Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Jiang Li; Qiu-Yan Chen; Jia He; Ze-Lei Li; Xiao-Feng Tang; Shi-Ping Chen; Chuan-Miao Xie; Yong-Qiang Li; Li-Xi Huang; Shu-Bio Ye; Miao-La Ke; Lin-Quan Tang; Huai Liu; Lu Zhang; Shan-Shan Guo; Jian-Chuan Xia; Xiao-Shi Zhang; Li-Min Zheng; Xiang Guo; Chao-Nan Qian; Hai-Qiang Mai; Yi-Xin Zeng
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

2.  Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma.

Authors:  Juan Lu; Xiao-Mei Chen; Hao-Ran Huang; Fei-Peng Zhao; Fan Wang; Xiong Liu; Xiang-Ping Li
Journal:  Head Neck       Date:  2018-03-01       Impact factor: 3.147

3.  Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.

Authors:  Noppadol Larbcharoensub; Komkrit Mahaprom; Chuleeporn Jiarpinitnun; Narumol Trachu; Nattha Tubthong; Poompis Pattaranutaporn; Ekaphop Sirachainan; Nuttapong Ngamphaiboon
Journal:  Am J Clin Oncol       Date:  2018-12       Impact factor: 2.339

4.  Tumor-infiltrating lymphocytes associate with outcome in nonendemic nasopharyngeal carcinoma: a multicenter study.

Authors:  Alhadi Almangush; Miia Ruuskanen; Jaana Hagström; Pasi Hirvikoski; Satu Tommola; Veli-Matti Kosma; Pentti Nieminen; Antti Mäkitie; Ilmo Leivo
Journal:  Hum Pathol       Date:  2018-07-18       Impact factor: 3.466

5.  Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A large-scale cohort study.

Authors:  Ya-Qin Wang; Yu-Pei Chen; Yu Zhang; Wei Jiang; Na Liu; Jing-Ping Yun; Ying Sun; Qing-Mei He; Xin-Ran Tang; Xin Wen; Xiao-Jing Yang; Pan-Pan Zhang; Jian Zhang; Yuan Lei; Ying-Qin Li; Jun Ma
Journal:  Int J Cancer       Date:  2018-02-09       Impact factor: 7.396

Review 6.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

Authors:  M J M Gooden; G H de Bock; N Leffers; T Daemen; H W Nijman
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

Review 7.  The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.

Authors:  Emma J de Ruiter; Marc L Ooft; Lot A Devriese; Stefan M Willems
Journal:  Oncoimmunology       Date:  2017-08-09       Impact factor: 8.110

8.  Immune infiltration in nasopharyngeal carcinoma based on gene expression.

Authors:  Meng-Si Luo; Guan-Jiang Huang; Bao-Xinzi Liu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

9.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

10.  Nasopharyngeal carcinoma: A review of current updates.

Authors:  Lei Wu; Churong Li; Li Pan
Journal:  Exp Ther Med       Date:  2018-02-20       Impact factor: 2.447

View more
  1 in total

1.  miR-212-5p inhibits nasopharyngeal carcinoma progression by targeting METTL3.

Authors:  Hongyu Zhou; Nana Zhang
Journal:  Open Med (Wars)       Date:  2022-07-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.